Moors & Cabot Inc. lifted its position in Zoetis Inc. (NYSE:ZTS) by 1.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,969 shares of the company’s stock after purchasing an additional 170 shares during the period. Moors & Cabot Inc.’s holdings in Zoetis were worth $929,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CGOV Asset Management raised its position in Zoetis by 2.7% during the first quarter. CGOV Asset Management now owns 169,605 shares of the company’s stock worth $12,059,000 after acquiring an additional 4,405 shares during the period. Victory Capital Management Inc. raised its position in Zoetis by 738.5% during the first quarter. Victory Capital Management Inc. now owns 243,747 shares of the company’s stock worth $13,008,000 after acquiring an additional 214,676 shares during the period. Cibc World Markets Corp raised its position in Zoetis by 51.7% during the first quarter. Cibc World Markets Corp now owns 51,383 shares of the company’s stock worth $2,742,000 after acquiring an additional 17,512 shares during the period. Neuberger Berman Group LLC raised its position in Zoetis by 1.2% during the first quarter. Neuberger Berman Group LLC now owns 4,629,099 shares of the company’s stock worth $247,055,000 after acquiring an additional 54,414 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Zoetis during the first quarter worth $294,000. Hedge funds and other institutional investors own 93.20% of the company’s stock.

Shares of Zoetis Inc. (NYSE ZTS) remained flat at $63.75 during midday trading on Friday. 2,543,606 shares of the stock traded hands. Zoetis Inc. has a 12 month low of $46.86 and a 12 month high of $65.83. The company has a market cap of $31.18 billion, a PE ratio of 36.04 and a beta of 1.02. The firm has a 50-day moving average of $63.41 and a 200-day moving average of $60.49.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, meeting the consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the previous year, the company posted $0.49 EPS. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. On average, equities research analysts predict that Zoetis Inc. will post $2.34 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be paid a $0.105 dividend. This represents a $0.42 annualized dividend and a yield of 0.66%. The ex-dividend date of this dividend is Wednesday, November 8th. Zoetis’s payout ratio is 23.73%.

A number of equities analysts have weighed in on the stock. BidaskClub cut shares of Zoetis from a “hold” rating to a “sell” rating in a research report on Friday. Cantor Fitzgerald restated a “buy” rating and set a $75.00 price objective on shares of Zoetis in a research report on Tuesday, September 26th. Stifel Nicolaus restated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research report on Friday, September 1st. Piper Jaffray Companies set a $73.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, August 25th. Finally, Cowen and Company set a $70.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research report on Thursday, August 24th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $65.44.

ILLEGAL ACTIVITY NOTICE: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/10/08/moors-cabot-inc-has-929000-position-in-zoetis-inc-zts.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.